It may be tempting for rosacea patients to stop treatment once their signs and symptoms have cleared up. But studies show that when used consistently according to directions, long-term medical therapy can slow or halt the progression of the disease and help maintain remission.

New recommendations urging dermatologists to place greater emphasis on persistent redness in rosacea were recently published in the Journal of Drugs in Dermatology. Titled “Update on Facial Erythema in Rosacea,” the article was based on a recent NRS roundtable to discuss this key aspect of the disorder in light of its recently updated standard classification system and standard management options, new burden-of-illness study results, and significant advances in medical therapy and patient care.

Physicians at the 2017 annual meeting of the American Academy of Dermatology discussed the many factors that may influence the effectiveness of medical therapy. 

Antibiotic resistance remains a concern among physicians and patients alike, said Dr. James Del Rosso, adjunct clinical professor of dermatology, Touro University College of Osteopathic Medicine. He noted that dermatologists tend to use antibiotics with patients for a longer period of time because they typically are used for their anti-inflammatory effects rather than to treat an infection. 

As with other chronic disorders that may involve multiple symptoms, a new NRS survey of 1,534 rosacea patients has documented that more than one therapy is often used over the course of managing the condition.

Nearly 80 percent of respondents reported that they had been prescribed more than one medication for their rosacea. Twenty-five percent had been prescribed two medications over the course of treatment, while 22 percent had used three and 29 percent four or more. 

In today’s increasingly complex health care system, it can be important to know the ins and outs of prescription insurance coverage in order to receive the medication that is intended by your doctor.

“With adequate knowledge, rosacea patients are empowered to take proactive measures that may be necessary to receive medical therapy appropriate for their individual cases,” said Dr. John Wolf, chairman of dermatology at Baylor College of Medicine.  “This can be especially important when prior authorizations and ‘step edits’ are required.”

While the ravages of subtype 3 (phymatous) rosacea have been well documented throughout history, today a multitude of options are available to restore a red, swollen or bumpy nose (rhinophyma) to normal appearance.

The knowledgeable use of cosmetics combined with topical medication prescribed by your dermatologist can camouflage the embarrassing redness, bumps and pimples of rosacea with a smooth appearance while medical therapy works to minimize or banish the underlying condition.

A recent patient survey by the National Rosacea Society has documented the importance of compliance with medical therapy, as 88 percent of the respondents said their symptoms reappear or increase in severity if they fail to use their medication as directed.

In the new survey, 74 percent of 658 respondents said they take their rosacea medications as prescribed by their physician. Another 17 percent said they sometimes use their medications as prescribed, and only 9 percent reported they do not follow their doctor's orders.

Although subtype 3 (phymatous) rosacea often involves excess tissue, it can be effectively treated with a range of options appropriate for the severity of the case, according to the standard management options for rosacea recently published by the National Rosacea Society.¹

Soothing cleansing and other measures in addition to medical therapy may help relieve the symptoms of subtype 4 (ocular) rosacea, according to the standard management options for rosacea recently published by the National Rosacea Society (NRS).

"Gentle care in keeping eyelids clean is especially important in keeping eyes with ocular rosacea healthy," said Dr. Marian Macsai, professor of ophthalmology at the University of Chicago and a member of the consensus committee and review panel of 26 medical experts who developed the new standard options.¹